Finally, we did not find significant differences in biomarker levels when comparing between clinical, genetic and (presumed) pathological FTD variants, except for NfL levels that were higher in PGRN mutation carriers compared with C9orf72 expansion carriers, possibly reflecting more aggressive disease in the former. Here, C9orf72 is linked to frontotemporal dementia.